Vanda Pharmaceuticals (VNDA) Retained Earnings (2010 - 2026)

Vanda Pharmaceuticals has reported Retained Earnings for 17 years, with the latest figure at $212000.0 in Q1 2026.

• Quarterly Retained Earnings fell 44.65% year-over-year to $212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212000.0 (down 44.65% YoY) and the FY2025 annual result came in at $629000.0, up 750.0% from the prior year.
• Retained Earnings declined to $212000.0 in Q1 2026 per VNDA's latest filing, from $629000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $702000.0 in Q3 2024 and troughed at -$170.6 million in Q1 2022.
• A 5-year average of -$38.0 million and a median of -$255000.0 in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 88957.29% in 2022, then jumped 750.0% in 2025.
• Over 5 years, Retained Earnings stood at -$1.2 million in 2022, then soared by 97.49% to -$30000.0 in 2023, then surged by 346.67% to $74000.0 in 2024, then surged by 750.0% to $629000.0 in 2025, then tumbled by 66.3% to $212000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $212000.0, $629000.0, and $540000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.